With diabetes competitive as ever, Novo launches Ozempic DTC campaign
Dive Brief:
- Against a backdrop of intense market competition, Novo Nordisk has rolled out a direct-to-consumer campaign for Ozempic, its once-weekly, injectable Type 2 diabetes medication.
- Set to the tune of Pilot's 1974 hit "Magic," the 90-second spot touts that a majority of adults in a study of the drug achieved lower blood sugar and A1C levels, which indicate average blood sugar in recent months, of less than 7%. A voiceover also says treatment with Ozempic may lead to weight loss, though on-screen text clarifies that it's not a weight loss drug.
- The commercial first aired on July 30 and has been nationally broadcast 122 times as of Wednesday, according to iSpot.tv, a television advertising analytics firm. Though Novo declined to comment on how much it has spent on the DTC campaign, iSpot.tv estimates the figure sits at about $950,000.
BIOPHARMA DIVE
Get pharma marketing intel in your inbox weekly
BioPharma Dive: Marketing is the weekly newsletter covering the top news & trends in pharma marketing.
GET THE FREE NEWSLETTERDive Insight:
While Novo's latest DTC effort carries an upbeat tone ? "Oh, oh, oh, Ozempic," sings a voice at the start of the commercial ? the Danish drugmaker will need more than magic to secure its place in the diabetes market. There, competition is stiff. For Type 2 diabetes alone, patients can try a sodium glucose co-transporter-2 inhibitor like Boehringer Ingelheim and Eli Lilly & Co.'s Jardiance (empagliflozin), or maybe a DPP-4 inhibitor like Merck & Co.'s Januvia (sitagliptin). A host of glucagon-like peptide-1 (GLP-1) analogs are also available, including Lilly's Trulicity (dulaglutide), AstraZeneca's?Byetta/Bydureon?(exenatide), and Novo's own Victoza (liraglutide) and Ozempic (semaglutide). What's more, Trulicity, Jardiance and Januvia are among the rivals already on the air with ad campaigns. The saturation has stung Novo, one of the big-three diabetes drugmakers along with Sanofi and Lilly. First quarter sales from its diabetes care and obesity business fell 5% year over year, while operating profit declined 8%. Not all of Novo's diabetes products are suffering, however. GLP-1s have proven to be bright spots in the company's portfolio, and potential sources of growth. "When we look at the therapy split on our products, you can see that the majority of our sales growth in the first quarter is coming from ... Victoza," Novo's Chief Financial Officer Karsten Munk Knudsen said during a May earnings call, adding that GLP-1 sales rose 20% in the U.S. and 12% outside the U.S. for the period. Though Knudsen described early sales for Ozempic as "benign," he also noted that was largely due to stocking from the product's launch and that new prescriptions (NRx) were ticking up nicely.Ozempic's GLP-1 NRx market share grows, but rivals remain daunting
Week of: March 2 | April 6 | May 4 | June 1 | July 6 | July 13 | July 20 | |
Ozempic | 717 | 1,418 | 2,297 | 2,603 | 3,763 | 4,611 | 4,898 |
Trulicity | 32,899 | 32,116 | 34,408 | 30,241 | 29,927 | 35,153 | 35,364 |
Victoza | 36,771 | 34,589 | 35,812 | 32,251 | 32,191 | 35,691 | 34,685 |
Bydureon | 10,653 | 10,324 | 10,760 | 9,214 | 8,962 | 10,527 | 10,714 |
SOURCE: Cowen & Co., Iqvia